Lupus Miliaris Disseminatus Faciei

Back

Background

Lupus miliaris disseminatus faciei (LMDF) is an uncommon, chronic, inflammatory dermatosis characterized by red-to-yellow or yellow-brown papules of the central face, particularly on and around the eyelids. Lesions may occur singly or in crops. Once considered a tuberculid because of the histology, many authors now consider LMDF to be an extreme variant of granulomatous rosacea. Others believe it is a distinct entity because of its characteristic histopathology and occasional involvement of noncentral facial areas.[1] Note the images below.



View Image

Lupus miliaris disseminatus faciei central facial papules. Courtesy of San Antonio Uniformed Services Health Education Consortium.



View Image

Lupus miliaris disseminatus faciei.

A variety of treatments are reportedly of some benefit, but controlled studies to establish the best treatment are lacking. Most clinicians find LMDF difficult to control; LMDF may result in disfiguring scarring. Etiology and pathogenesis are unknown. Active disease usually involves a 1- to 3-year course and resolves spontaneously.

In 2000, Skowron et al proposed a name change from LMDF to FIGURE (facial idiopathic granulomas with regressive evolution).[2] While the term LMDF is still widely used, the term FIGURE is now appearing in some publications.

Pathophysiology

Lupus miliaris disseminatus faciei (LMDF) affects only the skin. Studies have failed to demonstrate Mycobacterium tuberculosis or other mycobacterial disease by culture or polymerase chain reaction.[3] Extrapolating from theories of the pathogenesis of other forms of rosacea, some authors suggest that LMDF is a reaction to Demodex folliculorum. While the usual distribution coincides with that of most rosacea cases, an association with Demodex has not been confirmed. Others suggest that LMDF is a granulomatous reaction to hair follicle destruction or ruptured epidermal cysts.

Etiology

The etiology of lupus miliaris disseminatus faciei (LMDF) is unknown, but suggestions have included infection by M tuberculosis, atypical mycobacteria, tuberculids, foreign body granuloma (particularly to zirconium), reaction to cyst contents, and reaction to D folliculorum. Onset has been reported after stem cell transplantation.[4]

Epidemiology

Frequency

Lupus miliaris disseminatus faciei (LMDF) frequency is unknown; the disease is consider rare but may be more prevalent in Japan.

Race

Lupus miliaris disseminatus faciei (LMDF) may be more common in Asians, especially Japanese people.

Sex

Authors have stated that both sexes can be affected with lupus miliaris disseminatus faciei (LMDF); however, most published reports reviewed for this discussion and cited in the Bibliography describe solely or predominantly male patients.

Age

Young adults in their 20s most often are affected, although one report by Shitara described a woman in her early 70s.[5] Young adolescents also may be affected, and some authorities believe that chronic granulomatous periorificial disease of children (CGPD) is a form of lupus miliaris disseminatus faciei (LMDF) because histology and treatment response are the same.[6]

Prognosis

Prognosis for spontaneous resolution within 2 years is good. Therapy may help speed resolution. Recurrences are not described.

Patient Education

Educate patients about the nature of the disease to help alleviate anxiety and to establish realistic treatment expectations.

History

Most often, young adults with lupus miliaris disseminatus faciei (LMDF) have papules singly or in crops that are red, brown, or yellow-brown and appear on the central face, especially on and around the eyelids. Spontaneous resolution after crusting or pustulation within 1-3 years is standard. Residual scarring after individual papules regress may be disfiguring. Lesions occasionally may be generalized and appear on the extremities or trunk.

Physical Examination

Lupus miliaris disseminatus faciei (LMDF) manifests red, brown, or yellow-brown papules that appear singly or in crops. The papules appear on the central face, especially on and around the eyelids of young adults. They are found predominantly on the face in areas traditionally affected by rosacea.

Lesions occasionally may be generalized and appear on the extremities or trunk.[7] Axillary lesions may be mistaken for antiperspirant-related granulomas. Lesions may present later as crusts, pustules, and, ultimately, scars.

Imaging Studies

Imaging is not indicated for lupus miliaris disseminatus faciei (LMDF) unless sarcoidosis is suspected.

Other Tests

Tests are not indicated for lupus miliaris disseminatus faciei (LMDF) unless sarcoidosis is considered likely.

Procedures

Skin biopsy may be necessary if the diagnosis of lupus miliaris disseminatus faciei (LMDF) is in doubt. Biopsy may help distinguish LMDF from the more common granulomatous rosacea, sarcoidosis, or benign adnexal neoplasms such as syringomas. Potential complications of biopsy are scarring, infection, or insufficient biopsy material for diagnosis.

Histologic Findings

Early lupus miliaris disseminatus faciei (LMDF) lesions show superficial perivascular and periappendiceal lymphocytic infiltrates with a few histiocytes and neutrophils. Fully developed lesions show round granulomas, often with caseation necrosis.[8] The changes mimic miliary tuberculosis. Mixtures of sarcoidal and tuberculoid granulomas also may be seen. Late lesions show fibrosis with scattered lymphocytes, histiocytes, and neutrophils and also may be perifollicular and may show epidermal thinning. Note the image below.



View Image

Histopathology of lupus miliaris disseminatus faciei showing nodule with caseation necrosis. Image courtesy of Dr. Dirk Elston.

Medical Care

A variety of medical treatments reportedly are effective in lupus miliaris disseminatus faciei (LMDF), although controlled studies that support one treatment or group treatments as optimal are lacking. Reported therapies include the following:

Surgical Care

Scar revision procedures (laser resurfacing, dermabrasion, chemical peel) may benefit patients after the disease has run its course. Treatment with the 1450-nm diode laser has been reported to be effective. Pulse-dye laser has been used to successfully treat the erythema of rosacea, but its use in this condition has not been described.

Consultations

No consultations are indicated.

Diet

No dietary association (excess or deficiency) with lupus miliaris disseminatus faciei (LMDF) is described.

Activity

No physical activities or exposures are described that either improve or worsen lupus miliaris disseminatus faciei (LMDF).

Complications

Scarring (occasionally severe) is the primary complication of lupus miliaris disseminatus faciei (LMDF). Efforts to control the disease and minimize scarring are laudable; however, take care that patients do not unduly experience the complications of therapy for this self-limiting disease.

Prevention

Since the pathogenesis of lupus miliaris disseminatus faciei (LMDF) is unknown, prevention methods are difficult to define.

Medication Summary

Medical treatment of lupus miliaris disseminatus faciei (LMDF) often is unsuccessful. Anecdotal reports describe improvement with a variety of therapies, including prednisone, isotretinoin, tetracyclines, and vitamins (eg, riboflavin, pyridoxine). In the setting of LMDF, isotretinoin has been used alone or with systemic corticosteroids. Corticosteroids should be added only as a last resort.[15] Since LMDF spontaneously resolves within 1-2 years, the impact of therapy on the course of the disease is difficult to assess.

Prednisone (Deltasone, Meticorten, Orasone)

Clinical Context:  Prednisone may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.

Class Summary

Both topical and systemic corticosteroids have been used for their anti-inflammatory properties. In the literature, topical agents usually are described as ineffective; low-dose systemic agents reportedly work rapidly and well. Since LMDF may represent a form of rosacea, corticosteroids may provide temporary improvement, followed by chronic flaring of the disease. Caution is advised, and corticosteroids should not be administered unless other treatment options have failed.

Tetracycline (Sumycin)

Clinical Context:  Tetracycline's anti-inflammatory mechanism of action may differ from its antibacterial mechanism of action. Some studies indicate that tetracyclines inhibit inflammatory cell migration and transformation of lymphocytes. Tetracycline treats gram-positive and gram-negative organisms and mycoplasmal, chlamydial, and rickettsial infections. It inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunit(s).

Doxycycline (Vibra-Tabs, Vibramycin, Bio-Tab)

Clinical Context:  Doxycycline's anti-inflammatory effect may result from the inhibition of migration of inflammatory cells and transformation of lymphocytes. It inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Minocycline (Dynacin, Minocin)

Clinical Context:  Minocycline's anti-inflammatory effects may result from the inhibition of inflammatory cell migration and transformation of lymphocytes.

Class Summary

Tetracyclines are used for their anti-inflammatory rather than antibiotic effects. Most reports describe limited therapeutic benefit. This class includes tetracycline, doxycycline, and minocycline.

Isotretinoin (Accutane)

Clinical Context:  Isotretinoin is an oral agent that treats serious dermatologic conditions. Isotretinoin is the synthetic 13-cis isomer of the naturally occurring tretinoin (trans-retinoic acid). Both agents are structurally related to vitamin A. Isotretinoin should be prescribed only by physicians experienced and/or trained in its use.

Class Summary

Histology at various stages of the disorder suggests a follicular-based disorder, although the pathogenesis is unclear, and the predilection for eyelids is difficult to explain. How retinoids help is difficult to explain except in general terms relating to proper maturation and function of the follicular epithelium. Use of topical retinoids is not described in the literature, but presumably, they have been tried without benefit. Systemic retinoids cause severe birth defects. Adhere to current prescribing guidelines.

What is lupus miliaris disseminatus faciei (LMDF)?What is the pathophysiology of lupus miliaris disseminatus faciei (LMDF)?What causes lupus miliaris disseminatus faciei (LMDF)?What is the prevalence of lupus miliaris disseminatus faciei (LMDF)?What are the racial predilections of lupus miliaris disseminatus faciei (LMDF)?What are the sexual predilections of lupus miliaris disseminatus faciei (LMDF)?Which age groups have the highest prevalence of lupus miliaris disseminatus faciei (LMDF)?What is the prognosis of lupus miliaris disseminatus faciei (LMDF)?What is included in patient education about lupus miliaris disseminatus faciei (LMDF)?Which clinical history findings are characteristic of lupus miliaris disseminatus faciei (LMDF)?Which physical findings are characteristic of lupus miliaris disseminatus faciei (LMDF)?What are the differential diagnoses for Lupus Miliaris Disseminatus Faciei?What is the role of imaging studies in the workup of lupus miliaris disseminatus faciei (LMDF)?Which tests are performed in the workup of lupus miliaris disseminatus faciei (LMDF)?What is the role of skin biopsy in the workup of lupus miliaris disseminatus faciei (LMDF)?Which histologic findings are characteristic of lupus miliaris disseminatus faciei (LMDF)?How is lupus miliaris disseminatus faciei (LMDF) treated?What is the role of surgery in the treatment of lupus miliaris disseminatus faciei (LMDF)?Which specialist consultations are beneficial to patients with lupus miliaris disseminatus faciei (LMDF)?Which dietary modifications are used in the treatment of lupus miliaris disseminatus faciei (LMDF)?Which activity modifications are used in the treatment of lupus miliaris disseminatus faciei (LMDF)?What are the possible complications of lupus miliaris disseminatus faciei (LMDF)?How is lupus miliaris disseminatus faciei (LMDF) prevented?What is the role of medications in the treatment of lupus miliaris disseminatus faciei (LMDF)?Which medications in the drug class Retinoids are used in the treatment of Lupus Miliaris Disseminatus Faciei?Which medications in the drug class Tetracyclines are used in the treatment of Lupus Miliaris Disseminatus Faciei?Which medications in the drug class Corticosteroids are used in the treatment of Lupus Miliaris Disseminatus Faciei?

Author

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD, Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.

Additional Contributors

Jeffrey Meffert, MD, † Former Associate Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Disclosure: Nothing to disclose.

References

  1. van de Scheur MR, van der Waal RI, Starink TM. Lupus miliaris disseminatus faciei: a distinctive rosacea-like syndrome and not a granulomatous form of rosacea. Dermatology. 2003. 206(2):120-3. [View Abstract]
  2. Skowron F, Causeret AS, Pabion C, Viallard AM, Balme B, Thomas L. F.I.GU.R.E.: facial idiopathic granulomas with regressive evolution. is 'lupus miliaris disseminatus faciei' still an acceptable diagnosis in the third millennium?. Dermatology. 2000. 201(4):287-9. [View Abstract]
  3. Hodak E, Trattner A, Feuerman H, et al. Lupus miliaris disseminatus faciei--the DNA of Mycobacterium tuberculosis is not detectable in active lesions by polymerase chain reaction. Br J Dermatol. 1997 Oct. 137(4):614-9. [View Abstract]
  4. Zhang S, Liu XY, Cai L, Zhou C, Zhang JZ. A case of lupus miliaris disseminatus faciei after allogeneic hematopoietic stem cell transplantation. Chin Med J (Engl). 2019 Sep 5. 132 (17):2133-2134. [View Abstract]
  5. Shitara A. Lupus miliaris disseminatus faciei. Int J Dermatol. 1984 Oct. 23(8):542-4. [View Abstract]
  6. Misago N, Nakafusa J, Narisawa Y. Childhood granulomatous periorificial dermatitis: lupus miliaris disseminatus faciei in children?. J Eur Acad Dermatol Venereol. 2005 Jul. 19(4):470-3. [View Abstract]
  7. Kalyanpad YN, Dongre AM, Gole PV, Khopkar US. Extrafacial lupus miliaris disseminatus faciei: A rare entity. Indian J Dermatol Venereol Leprol. 2017 Mar 31. [View Abstract]
  8. el Darouti M, Zaher H. Lupus miliaris disseminatus faciei--pathologic study of early, fully developed, and late lesions. Int J Dermatol. 1993 Jul. 32(7):508-11. [View Abstract]
  9. Uesugi Y, Aiba S, Usuba M, Tagami H. Oral prednisone in the treatment of acne agminata. Br J Dermatol. 1996 Jun. 134(6):1098-100. [View Abstract]
  10. Shimizu A, Funasaka Y, Ueno T, Kanzaki A, Saeki H. Case of lupus miliaris disseminatus faciei associated with marked formation of cysts, successfully treated with intralesional injections of triamcinolone acetonide. J Dermatol. 2017 Mar 24. [View Abstract]
  11. Tokunaga H, Okuyama R, Tagami H, Aiba S. Intramuscular triamcinolone acetonide for lupus miliaris disseminatus faciei. Acta Derm Venereol. 2007. 87(5):451-2. [View Abstract]
  12. Ferguson L, Fearfield L. Topical dapsone gel is a new treatment option for acne agminata. Clin Exp Dermatol. 2018 Sep 23. [View Abstract]
  13. Berbis P, Privat Y. Lupus miliaris disseminatus faciei: efficacy of isotretinoin. J Am Acad Dermatol. 1987 Jun. 16(6):1271-2. [View Abstract]
  14. Koike Y, Hatamochi A, Koyano S, Namikawa H, Hamasaki Y, Yamazaki S. Lupus miliaris disseminatus faciei successfully treated with tranilast: Report of two cases. J Dermatol. 2011 Jun. 38(6):588-92. [View Abstract]
  15. Yin S, Sun L. Case report: A successful combined treatment of severe lupus miliaris disseminatus faciei with oral isotretinoin and methylprednisolone. Dermatol Ther. 2020 Feb 13. e13267. [View Abstract]

Lupus miliaris disseminatus faciei central facial papules. Courtesy of San Antonio Uniformed Services Health Education Consortium.

Lupus miliaris disseminatus faciei.

Histopathology of lupus miliaris disseminatus faciei showing nodule with caseation necrosis. Image courtesy of Dr. Dirk Elston.

Histopathology of lupus miliaris disseminatus faciei showing nodule with caseation necrosis. Image courtesy of Dr. Dirk Elston.

Lupus miliaris disseminatus faciei central facial papules. Courtesy of San Antonio Uniformed Services Health Education Consortium.

Lupus miliaris disseminatus faciei.